Osteoporosis News and Research

Latest Osteoporosis News and Research

Public health policy should stress on reduction in sodium intake

Reducing sodium intake is a major public health priority that must be acted upon by governments and nongovernmental organizations to improve population health, states an article http://www.cmaj.ca/press/cmaj090361.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

15 Sep 2009

First FOSAMAX case declared as mistrial by the U.S.District Court Judge

Merck & Co., Inc. said today that a mistrial was declared by U.S. District Court Judge John F. Keenan in Boles v. Merck, the first FOSAMAX case to go to trial. This case was the Plaintiffs’ Steering Committee's first choice to take to trial. The Boles case was tried in New York federal court and involved a Florida woman who blamed her dental and jaw problems on FOSAMAX.

14 Sep 2009

PTH therapy could prevent osteoarthritis

An existing osteoporosis drug is the first ever found to prevent cartilage loss from osteoarthritis following injury to a joint, and may also regenerate some cartilage that has been lost to osteoarthritis, according to an early study presented today at the annual meeting of the American Society for Bone and Mineral Research in Denver.

14 Sep 2009

Research data reveals why women discontinue treatment with current osteoporosis therapies

Amgen Inc. today announced the presentation of data highlighting the links between medication satisfaction, adherence to therapy and fracture risk reduction among women with postmenopausal osteoporosis. The data were presented at the 31st annual meeting of the American Society for Bone Mineral Research (ASBMR).

14 Sep 2009

New data reveals the efficacy of Instanyl in management of breakthrough cancer pain

New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer.

11 Sep 2009

Efficacy of Instanyl in management of breakthrough cancer pain demonstrated

11 Sep 2009

Physicians and patients underestimate promotional volume of Actonel

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that patients and physicians most frequently recall Roche's Boniva messages among the ten surveyed osteoporosis brands likely as a result of the Sally Field marketing campaign.

10 Sep 2009

Lack of physical activity is linked to childhood obesity

It's the start of another school year and Canadian physiotherapists are taking this opportunity to talk tough about the epidemic of overweight and inactive children in this country. According to Statistics Canada about 25 percent of Canadian children are overweight. The Active Healthy Kids Canada 2009 Report Card found that only 13 percent of children and youth are getting the 90 minutes of physical activity recommended by Canada's Physical Activity Guide.

9 Sep 2009

First results of European survey of cancer patients' experience of breakthrough pain presented at EFIC

The first results of the first European survey of cancer patients' experience of breakthrough pain were presented today at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC).

9 Sep 2009

Consumers seek functional foods and supplements to enhance wellness quotient

An expanding aging population and increased consumer awareness boosts growth for the U.S. bone and joint health ingredients market. Consumers increasingly seek supplements and functional foods that enhance their wellness quotient and have strong scientific backup.

3 Sep 2009

Validity of Unigene’s patent on Fortical confirmed by the court

Unigene Laboratories, Inc. has reported that the U.S. District Court, Southern District of New York, has confirmed the validity of Unigene’s patent on Fortical and issued an order permanently enjoining Apotex Inc. and Apotex Corp. from further infringement of the patent.

3 Sep 2009

Estrogen supplements do not suppress bone loss in postmenopausal women

Dietary supplements claiming to help postmenopausal women with bone health may not be doing what they say, according to new research from Purdue University.

3 Sep 2009

Pacific Biometrics enters into a Loan and Security Agreement to raise $4 million

Pacific Biometrics, Inc. (OTC Bulletin Board: PBME), a leading provider of specialized reference laboratory and contract research services, today announced the Company's entry into a Loan and Security Agreement with Terry M. Giles, providing for a $4 million loan (the "Loan") to the Company.

2 Sep 2009

Gene causing periodontitis, rheumatoid arthritis and osteoporosis identified

Investigators at Hospital for Special Surgery, collaborating with researchers from other institutions, have contributed to the discovery that a gene called interferon regulator factor-8 (IRF-8) is involved in the development of diseases such as periodontitis (gum disease), rheumatoid arthritis and osteoporosis. The study, which will be published online August 30, ahead of print, in the journal Nature Medicine, could lead to new treatments in the future.

2 Sep 2009

Waist-hip ratio is a better of measure of obesity in older patients

Body mass index (BMI) readings may not be the best gauge of obesity in older adults, according to new research from UCLA endocrinologists and geriatricians. Instead, they say, the ratio of waist size to hip size may be a better indicator when it comes to those over 70.

2 Sep 2009

MammoSite ML radiation therapy system approved for breast cancer treatment

Hologic, Inc. (Hologic or the Company), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the U.S. Food and Drug Administration (FDA) cleared the Company's 510K application for the MammoSite((R)) ML radiation therapy system.

1 Sep 2009

Medivir adds MIV-711 to bone-related disorder treatment candidate portfolio

Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir’s existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.

1 Sep 2009

TransPharma's Phase 2A trial of ViaDerm-hPTH(1-34) for treating severe osteoporosis is successful

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of the Phase 2A trial of ViaDerm-hPTH(1-34) which is being developed for the treatment of severe osteoporosis.

1 Sep 2009

New technique developed for the treatment of cancer

A new paradigm in the way we look at cancer with important implications on how we treat it is about to be published in the British Journal of Cancer by Portuguese, Belgian and American researchers.

1 Sep 2009